2025. Efficacy and Safety of Tyrosine Kinase 2 Inhibitor Deucravacitinib in Psoriasis : A Systematic Review and Drug-Response Meta Analysis of RCTs. JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia. (Dec. 2025), 10. DOI:https://doi.org/10.53366/jimki.vi.961.